Hyperhomocysteinemia and Cardiovascular Risk

Clinical Significance and Risk Quantification

A high homocysteine level indicates significantly increased cardiovascular risk, particularly a 2- to 3-fold increased risk of atherosclerotic vascular disease, including stroke, coronary artery disease, and venous thromboembolism 1, 2, 3
For every 5 μmol/L increase in homocysteine, stroke risk increases by 59% (95% CI, 29-96%) 2, 3
For every 3 μmol/L decrease, stroke risk decreases by 24% (95% CI, 15-33%) 2, 3
An increment of 5 mmol/L in total homocysteine confers equivalent coronary artery disease risk to a 20 mg/dL increase in plasma cholesterol 3
Homocysteine accounts for up to 10% of the population's coronary artery disease risk 3
Even moderately elevated levels (10-15 μmol/L) may confer graded increased cardiovascular risks 1

Folate deficiency is a cofactor for methylenetetrahydrofolate reductase (MTHFR) in the remethylation pathway 1, 2, 5
Vitamin B12 (cobalamin) deficiency is also a cofactor for MTHFR 1, 2, 5
Vitamin B6 (pyridoxine) deficiency is a cofactor for cystathionine β-synthase in the transsulfuration pathway 1, 2, 5
Cystathionine β-synthase deficiency causes severe hyperhomocysteinemia in the transsulfuration pathway 1, 5
MTHFR deficiency or thermolabile variant (C677T mutation) significantly increases hyperhomocysteinemia risk 1, 5

Obtain fasting plasma homocysteine level after at least 8 hours of fasting; a single elevated value should be retested for confirmation 5
Measure serum and erythrocyte folate levels to assess folate status (erythrocyte folate reflects long-term status) 5
Check serum cobalamin (vitamin B12) to identify B12 deficiency 5
Measure serum or urine methylmalonic acid (MMA) to confirm true B12 deficiency 5
Assess renal function (creatinine, eGFR) to evaluate for decreased clearance 2, 5

The American Heart Association/American Stroke Association states that B-complex vitamins (cobalamin/B12, pyridoxine/B6, and folic acid) might be considered for prevention of ischemic stroke in patients with hyperhomocysteinemia (Class IIb; Level of Evidence B) 2, 3
Folic acid 0.4-1 mg daily reduces homocysteine by approximately 25-30%; adding vitamin B12 (0.02-1 mg daily) provides an additional 7% reduction 3, 5
Combination therapy with folic acid (0.4-5 mg/day), vitamin B12 (0.02-1 mg/day), and vitamin B6 (10-50 mg/day) is recommended for intermediate hyperhomocysteinemia 5
High-dose pyridoxine (50-250 mg/day) combined with folic acid (0.4-5 mg/day) and/or vitamin B12 (0.02-1 mg/day) is recommended for severe hyperhomocysteinemia 5

The HOPE-2 study showed a 25% stroke reduction (RR 0.75; 95% CI, 0.59-0.97) with combination B6, B12, and folic acid therapy 3, 6
Meta-analysis of folic acid supplementation showed an 18% reduction in stroke risk 3
However, trials in patients with established vascular disease (NORVIT, VISP) showed inconsistent cardiovascular benefits despite lowering homocysteine 4, 6